www.april19.ai Open in urlscan Pro
34.249.200.254  Public Scan

Form analysis
1 forms found in the DOM

Name: wf-form-Contact-Form — GET

<form id="wf-form-Contact-Form" name="wf-form-Contact-Form" data-name="Contact Form" method="get" class="form" data-wf-page-id="603d15d576ef1a6f1150778b" data-wf-element-id="ba5c74f0-b128-bfcc-9af8-72e98c397926" aria-label="Contact Form"
  data-cb-wrapper="true">
  <div class="contact-form-grid">
    <div id="w-node-ba5c74f0-b128-bfcc-9af8-72e98c397928-1150778b"><label for="First-Name" id="contact-first-name" class="field-label">First Name *</label><input class="text-field-2 w-input" maxlength="256" name="First-Name" data-name="First Name"
        placeholder="" type="text" id="First-Name" required=""></div>
    <div id="w-node-ba5c74f0-b128-bfcc-9af8-72e98c39792c-1150778b"><label for="Last-Name" id="contact-last-name" class="field-label">Last Name *</label><input class="text-field w-input" maxlength="256" name="Last-Name" data-name="Last Name"
        placeholder="" type="text" id="Last-Name" required=""></div>
    <div id="w-node-_7ee2df34-a86b-e99a-8c25-4940485bd0ae-1150778b"><label for="Email" id="contact-email" class="field-label">Email *</label><input class="text-field-3 w-input" maxlength="256" name="Email" data-name="Email" placeholder=""
        type="email" id="Email" required=""></div>
    <div id="w-node-ba5c74f0-b128-bfcc-9af8-72e98c397938-1150778b"><label for="Message" id="contact-message" class="field-label">Message</label><textarea data-name="Message" maxlength="5000" id="Message" name="Message" placeholder="Example text"
        class="textarea w-input"></textarea></div>
  </div>
  <div data-sitekey="6Ld8F1QpAAAAAPDk7-Se6zoHspEbQB5X3cUtUDtP" class="w-form-formrecaptcha g-recaptcha g-recaptcha-error g-recaptcha-disabled">
    <div style="width: 304px; height: 78px;">
      <div><iframe title="reCAPTCHA" width="304" height="78" role="presentation" name="a-hyzt5vrw26m" frameborder="0" scrolling="no"
          sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-top-navigation allow-modals allow-popups-to-escape-sandbox allow-storage-access-by-user-activation"
          src="https://www.google.com/recaptcha/api2/anchor?ar=1&amp;k=6Ld8F1QpAAAAAPDk7-Se6zoHspEbQB5X3cUtUDtP&amp;co=aHR0cHM6Ly93d3cuYXByaWwxOS5haTo0NDM.&amp;hl=de&amp;v=MHBiAvbtvk5Wb2eTZHoP1dUd&amp;size=normal&amp;cb=olzm39r2za2r"></iframe></div>
      <textarea id="g-recaptcha-response" name="g-recaptcha-response" class="g-recaptcha-response" style="width: 250px; height: 40px; border: 1px solid rgb(193, 193, 193); margin: 10px 25px; padding: 0px; resize: none; display: none;"></textarea>
    </div><iframe style="display: none;"></iframe>
  </div>
  <div class="formbuttons"><input type="submit" data-wait="Please wait..." class="submit-button w-button" value="Submit">
    <div class="socialmediabuttonblock">
      <a href="https://twitter.com/april19ai" class="twitterlink w-inline-block"><img src="https://assets-global.website-files.com/603d15d576ef1a473c50778a/63652432bc034964d1bdacb6_5296514_bird_tweet_twitter_twitter%20logo_icon.png" loading="lazy" alt="" class="socialmediaicon twittericon"></a><a href="https://www.linkedin.com/company/april19ai" class="linkedinlink w-inline-block"><img src="https://assets-global.website-files.com/603d15d576ef1a473c50778a/63652432f7934fa5f6b3b4b2_5296501_linkedin_network_linkedin%20logo_icon.png" loading="lazy" alt="" class="socialmediaicon"></a>
    </div>
  </div>
</form>

Text Content

MissionProblemTechnologyScienceTeamTeamResearchNewsContact




AI-DRIVEN PSYCHEDELIC DRUG DISCOVERY
BEYOND MENTAL HEALTH

We are a drug development company integrating AI with computational chemistry to
design and develop the next generation of psychedelic-inspired compounds. By
optimizing psychedelics with a unique pharmacology identified in academic
research, April19 seeks to expand the utility of psychedelics beyond mental
health into neurodegenerative indications and healthy longevity.


OUR MISSION

Classical psychedelics are showing breakthrough therapeutic potential in mental
health, laying foundations for a fascinating new class of therapeutics. We
deeply respect these compounds and the legacy of indigenous people and research
pioneers who discovered the amazing healing power of the psychedelic experience.


Standing on the shoulders of these giants, we have identified a unique
opportunity to use basic principles of psychedelic action to heal not only
mental health, but also to restore cognitive abilities lost through age-related
neurodegeneration.

Combining together the latest in AI-powered computational chemistry and
psychedelic drug design, we are developing a unique class of compounds, which
may provide a much-needed answer to the ever-rising threat of cognitive decline
and dementia in our constantly aging population.



Psilocybe cyanescens - photo by Maks Houbit


OVERCOMING LIMITATIONS OF CURRENT PSYCHEDELICS


 * 
   Even though research shows certain psychedelics have promising effects on
   neurological health in short-term laboratory experiments, the therapeutic
   approaches currently studied in clinical trials are not optimal for long-term
   treatment of elderly patients, especially in advanced states of
   neurodegeneration.
 * High-dose treatment (psychedelic-assisted psychotherapy)
   Psychedelic-assisted psychotherapy uses psychedelics in high doses, which is
   mentally demanding, has many contraindications and requires a considerable
   time commitment from a specially trained psychotherapist. It was designed for
   and will likely be suitable only for mental health disorders.
 * Low-dose treatment (microdosing)
   ‍In microdosing, low or “subperceptual” doses are administered regularly,
   however, tolerance build-up caused by most psychedelics results in
   diminishing or inconstant therapeutic action. Clinical trials have not yet
   shown significant therapeutic efficacy or even long-term safety (due to risk
   of 5-HT2B-mediated cardiotoxicity).
 * "Nonpsychedelic psychedelics” (psychoplastogens)
   Some researchers are exploring derivatives of psychedelics that apparently
   produce therapeutic action (in animal models of mental health disorders) with
   no or minimal psychedelic effects. These compounds likely have a unique
   mechanism of antidepressant action, different from the distinctive
   psychedelic action that is promising in neurodegeneration.


OUR DRUG DESIGN PLATFORM

There are more potential drug-like compounds than there are atoms in the
observable universe. Each of these potential molecules then has its own unique
pattern of binding to the tens of thousands of molecular targets within our
body. It is then no surprise that finding a therapeutic with the right binding
profile and optimal properties by standard screening requires an enormous amount
of money and time.

That is why we have developed a suite of AI-driven computational models and
tools that allow us to efficiently search the immense chemical space for drug
candidates matching a desired pattern.

These tools allow us to screen billion-compound libraries, automatically
generate novel targeted molecules, predict hundreds of complex molecular
properties or even evolve drugs through structural mutation and crossover.

Copying nature’s ingenuity and effectiveness, our AI platform can greatly
accelerate hit identification and lead optimization, while also providing higher
quality candidates and improve our decision making throughout the development
process.





OUR SCIENCE

The foundations of our scientific hypothesis originate from our research project
that started four years ago at the University of Chemistry and Technology in
Prague (UCT) and later included computational work done at University College
London (UCL).

Inspired by seminal research into neuroplasticity and mechanisms of psychedelic
action published at that time, this project had discovered that a largely
unexplored class of psychedelic compounds may provide significant therapeutic
benefits over classical psychedelics, according to both preclinical and clinical
evidence. The bulk of the project then combined computational drug design with
organic synthesis to eventually yield two distinct series of promising drug
candidates.

Our strategy involves progressing the development of compounds synthesized at
UCT as well as using the full capabilities of our AI platform to optimize,
improve or design new compounds with this unique pharmacology.

We believe that enhancing neurorestorative and neuroprotective effects while
reducing tolerance buildup and cardiotoxicity will enable safe and effective
long-term daily dosing, even for elderly patients. Such compounds would then
constitute ideal candidates for psychedelic treatment of neurodegenerative
disorders and provide a powerful tool for our mental healthspan extension.

‍


As a result of their unique binding profile, these compounds may provide a range
of benefits over first generation psychedelics, such as:

 * Providing both acute and long-term effects by activating multiple
   neuroplasticity-related pathways

 * Lower reliance on 5-HT2A psychedelic target for its effects, resulting in:
    * More neuroplastic and neurogenic effects than hallucinogenic ones – fewer
      contraindications
    * Lower tolerance build-up – allowing regular pharmacotherapy
    * Lower 5-HT2B ligand similarity – lower cardiotoxicity risk

 * Innate neuroprotective and neurorestorative effects – added benefit for
   neurodegenerative disorders, neural injuries, and elderly or vulnerable
   patients


FOUNDING TEAM

Our experience in entrepreneurship, applied AI, software development &
psychedelic drug design make us a well-rounded team, ready for the new era of
drug discovery.



DR RICHARD DALLAWAY

Combined expertise in machine learning and software engineering

Long history of successfully applying AI in different fields

LinkedIn


ING. JÁCHYM FIBÍR, MSC

Medicinal chemistry and pharmacology

4 years of research in psychedelic drug design, including an MSc at UCL


LinkedIn


SURAN GOONATILAKE, OBE

AI entrepreneur
‍
Co-founder of AI startup Searchspace ($150m exit)
‍
Professor at UCL Centre for AI

LinkedIn


SCIENTIFIC ADVISORY BOARD


April19's advisors bring a wide range of experience and expertise, including
computational drug design and cheminformatics, organic synthesis of psychoactive
drugs and their legal handling, and preclinical assays of neurodegeneration with
classical psychedelics:


URSZULA KOZLOWSKA PH.D


Dr. Kozlowska is a Principal Investigator in psychedelic basic research at the
Polish Academy of Sciences (PAS), with a particular focus on the potential
therapeutic application of psychedelics to stop the progress of
neurodegeneration and rescue brain damage. Her research in the immunological
aspects of the process of degeneration and regeneration of neural tissue aligns
well with April19's mission to discover novel psychedelics for neurodegenerative
disorders. Dr. Kozlowska has extensive experience in the bench-to-bedside
process of discovering novel therapeutic solutions in basic, preclinical, and
clinical studies. Being an enthusiast in neuroscience and regenerative medicine,
her previous research was in neural and mesenchymal stem cells and their
clinical applications, giving her a unique perspective on the field of longevity
research from the eyes of a neuroscientist. Her workplace at PAS offers a unique
partnership opportunity for assessing how April19 proprietary compounds perform
in both in vitro and in vivo models of neurodegeneration, relative to first
generation psychedelics.


ASSOC. PROF. ING. MARTIN KUCHAŘ, PH.D


Associate professor Kuchař is acting Head of the Forensic Laboratory of
Biologically Active Substances (BAFA) at the University of Chemistry and
Technology in Prague (UCT), where April19 co-founder Jáchym Fibír discovered and
synthesized our unique class of psychedelic-inspired compounds. As a bioorganic
chemist with over 10 years of experience in neuropsychopharmacological research
and forensic toxicology, he is well-positioned to advise April19 on the
development of novel psychoactive compounds. He facilitates the partnership
between BAFA and April19, helping to find the best possible arrangement for
resource sharing in the joint development of these compounds. At BAFA, he
focuses on the synthesis of pure alkaloids, their metabolism, and
pharmacological characteristics, which are critical for the development of safe
and effective drugs. Furthermore, as an active member of the International
Forensic Toxicological Society, his expertise with both legal and illegal
narcotics and psychotropic substances is invaluable for ensuring that the
development of novel psychedelics meets legal requirements.



PROF. ING. DANIEL SVOZIL, PH.D


As the Head of the Department of Informatics and Chemistry at UCT Prague, and
the creator and guarantor of BSc, MSc, and Ph.D study programs in
bioinformatics, professor Svozil has over 20 years of experience in structural
bioinformatics, computational drug design and computational chemical biology.
His research interests include virtual screening and chemical space exploration,
de novo molecular design using deep learning approaches, synthetic accessibility
prediction, and molecular target identification—all directly relevant to
April19's mission to design and develop novel psychedelics using AI. His broad
expertise in cheminformatics, particularly in integrating the latest AI models
and computational techniques, will help us accelerate the drug discovery process
and identify novel psychedelics that might not be discoverable through
traditional methods. Moreover, having access to his professional network will
enable us to identify and hire highly-skilled computational chemists in the
field of AI-assisted drug discovery.



APRIL19 PEER-REVIEWED RESEARCH


Molecular Fingerprint VAE

Faster exploration of the chemical space and similarities from a highly compact
molecular representation.

How to Reward Your Drug Agent?

A framework for evaluating our generative algorithms for use in novel drug
creation.

PEPSI: Post-docking Evaluation with Protein-Small Molecules Interaction

Exploring order-of-magnitude speed ups for docking, using cutting-edge deep
learning models.


NEWS

National Geographic: Why scientists want to create better psychedelics (and
April19's part in that)
Pharmaceutical Technology: How AI could unlock the medical potential of
psychedelics
Vice: The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
LA Weekly Interview: AI discovers new compounds
April19 and CAS collaborate to accelerate real-world application of AI to
discovery of novel mental health therapeutics
Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™
MagicMed Industries announces collaboration with April19
MagicMed and Proactive Present Magic Moments AI in Psychedelics
MagicMed Industries bring a fresh approach to development of Psilocybin
MagicMed Industries looking to unlock the full potential of psychedelic
PSYC Provides an Update on Its Investment into The Conscious Fund



CONTACT

Follow us on LinkedIn and Twitter to stay updated. You can also message us there
to say hello!

If you have enquires about April19, such as press or investment interest, please
drop us an email at hello@april19.ai or use the form below.


First Name *
Last Name *
Email *
Message


Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.